MRL


<



They have been turning us into a large molecule company for years, this is nothing new. Just look at Organon spinoff, all acquisitions are large molecule…The EC and MRL leadership believe the company must get leaner, more nimble and yes with that will come reductions.,
 








We need to be aggressive in acquisitions, products on market and late stage clinical compounds…we pump billions into R&D, what have our scientists actually come up with? Very little
 








Similar threads

Replies
0
Views
2K
Merck
anonymous
Replies
11
Views
3K
Merck
anonymous
Replies
16
Views
5K
Merck
anonymous
Replies
2
Views
1K
Merck
anonymous
Replies
9
Views
2K
Merck
anonymous